Industry News
Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib Monotherapy antitumor activity observed, including confirmed partial response and several patients with long stable disease Identified both intermittent and continuous schedules to enable combination studies Encouraging early responses across gemcitabine, camonsertib and FOLFIRI clinical combinations Repare to…
Read More
Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000 Excerpt from the Press Release: MALVERN, Pa., June 07, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, today announced additional results from its…
Read More
The new test can diagnose the difficult-to-diagnose diseases in seconds with high certainty, beating out previous invasive methods like the spinal tap. Excerpt from the Press Release: Researchers from Ottawa’s Carleton University have developed a rapid, saliva-based test that can reliably detect signs of Alzheimer’s and Parkinson’s early on in the diseases’ development. The team’s…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced the dosing of its first patient with AVD-104 in its Phase 2 SIGLEC Trial today by Ashkan Abbey, MD of Texas Retina Associates…
Read More
Favorable long-term, open-label treatment data from nearly 500 patients in real-world setting suggest that patient-tailored, as-needed administrations of fasedienol over time were safe and well-tolerated Positive exploratory fasedienol efficacy data measured by the Liebowitz Social Anxiety Scale (LSAS) demonstrated clinically meaningful reductions in fear, anxiety and avoidance of anxiety-provoking social and performance situations in daily…
Read MoreSummit Therapeutics is Currently Enrolling in a Phase III Study with Additional Phase III Study Planned for Third Quarter 2023 for Ivonescimab Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be…
Read More
The study will build upon previous studies conducted by Ghosh and her collaborators that have explored the ways social inequality contribute to unequal cancer control outcomes Excerpt from the Press Release: n January of this year, Debarchana (Debs) Ghosh, associate professor in the Department of Geography in the College of Liberal Arts and Sciences (CLAS)…
Read More
Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with a Profile that Strongly Supports Further Clinical Development Efforts AX-158 is Being Developed for Once Daily Oral Dosing to Address Autoimmune Diseases by Providing Immunomodulation without Immunosuppression Excerpt from the Press Release: CAMBRIDGE, Mass., June 1, 2023 /PRNewswire/ — Artax Biopharma, Inc., a…
Read More
Excerpt from the Press Release: eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced positive interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in patients with ER+ metastatic breast cancer (mBC).…
Read More
Excerpt from the Press Release: Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held at McCormick Place in Chicago, Illinois and virtually from June 2-6,…
Read More